

## Gemeinsame Publikationen der D-A-CH Gruppe

1. Aivado M, Rong A, Stadler M, Germing U, et al . Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. *Eur J Haematol*. 2002;68(4):210-6.
2. Aul C, Giagounidis A, Germing U, Ganser A. Evaluating the prognosis of patients with myelodysplastic syndromes. *Ann Hematol*. 2002 ;81(9):485-97
3. Aul C, Giagounidis A, Germing U, Ganser A. Myelodysplastic syndromes. Diagnosis and therapeutic strategies. *Med Klin* 2002;15;97(11):666-76
4. Aul C, Giagounidis A, Heinsch M, Germing U, Ganser A: Prognostic indicators and scoring system for predicting outcome in patients with MDS. *Rev Clin Exp Hematol*. 2004,1;8(2)
5. Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, Lubbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kundgen A, Müller T, Haas R, Gattermann N, Aul C. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). *Leukemia*. 2005;19(12):2223-31.
6. Germing U, Platzbecker U, Giagounidis A, Aul C. Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. *Br J Haematol*. 2007 ;138(3):399-400.
7. Giagounidis AA, Haase S, Germing U, et al. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. *Ann Hematol*. 2005;84(6):389-94.
8. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis AA, Aul C, Trümper L, Krieger O, Stauder R, Müller TH, Wimazal F, Valent P, Fonatsch C, Steidl C. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. *Blood*. 2007 Dec 15;110(13):4385-95.
9. Kuendgen A, Lübbert M. Current status of epigenetic treatment in myelodysplastic syndromes. *Ann Hematol*. 2008 Aug;87(8):601-11.
10. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, et al . The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. *Cancer*. 2006; 1; 106(1):112-9.
11. Pitako JA, Haas PS, Van den Bosch J, Müller-Berndorff H, Kundgen A, Germing U, et al. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine. *Ann Hematol*. 2005;84 Suppl 13:25-31.
12. Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott BL, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorrow ML, Ehninger G, Deeg HJ. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). *Biol Blood Marrow Transplant*. 2008 Nov;14(11):1217-25.
13. Platzbecker U, Germing U, et al Association with the single-nucleotide polymorphism (Glu785Lys) of the G-CSF receptor with high-risk MDS and AML with multilineage dysplasia. *Leukemia*, 2006, Dec; 20(12): 2188-9

14. Stadler M, Germing U, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immunomodulating therapy in patients with low-risk myelodysplastic syndromes. *Leukemia* 2004;18(3):460-5.
15. Steidl C, Steffens R, Gassmann W, Hildebrandt B, Hilgers R, Germing U, et al Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. *Leuk Res.* 2005; 29(9):987-93.
16. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, et al . Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. *Leuk Res.* 2007 ;31(6):727-36.
17. Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, Lübbert M, Stauder R, Giagounidis A, Valent P, Pfeilstöcker M. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. *Ann Oncol.* 2009 Jul 15
18. Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U. Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes. *Ann Hematol.* 2009 Jul;88(7):607-11. Epub 2009 Jan 16.
19. Wimazal F, et al Evaluation of prognostic significance of eosinophilia and basophilia in a larger cohort of patients with MDS. *Cancer.* (2009) in press

#### **under review**

1. Recommendations for the use of 5-Azacytidine in MDS Götze K. et al.

submitted to *Ann Hematology*

#### **Abstracts, Meeting Reports, Oral Presentations**

1. PROGNOSTIC SIGNIFICANCE OF EOSINOPHILS AND BASOPHILS IN MDS: EVALUATION OF A CORE DATA SET OF 1008 MDS PATIENTS  
 Author(s): Wimazal, F; Germing, U; Kundi, M; et al.  
 Source: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Volume: 94  
 Pages: 1347 Published: 2009 Conference Title: 14th Annual Meeting of the European-Hematology-Association Conference Date: JUN 04-07, 2009 Conference Location: Berlin, GERMANY

2. CLINICAL AND PROGNOSTIC CHARACTERISTICS OF 484 PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROME (T-MDS) OR ACUTE MYELOID LEUKEMIA (T-AML)  
 Author(s): Kundgen, AK; Haase, D; Giagounidis, A; et al.  
 Source: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Volume: 93  
 Pages: 0708 Published: 2008 Conference Title: 13th Congress of the European-Hematology-Association Conference Date: JUN 12-15, 2008 Conference Location: Copenhagen, DENMARK
3. RISK FACTORS FOR AML TRANSFORMATION AND MORTALITY IN TRANSFUSION-DEPENDENT DELETION SQ MDS  
 Author(s): List, AF; Giagounidis, A; Brandenburg, N; et al.  
 Source: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Volume: 93  
 Pages: 0714 Published: 2008 Conference Title: 13th Congress of the European-Hematology-Association Conference Date: JUN 12-15, 2008 Conference Location: Copenhagen, DENMARK
4. PROGNOSTIC IMPACT OF ADDITIONAL CHROMOSOMAL ABERRATIONS TO 5Q-IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROMES  
 Author(s): Mallo, M; Cervera, J; Schanz, J; et al.  
 Source: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Volume: 93  
 Pages: 0906 Published: 2008 Conference Title: 13th Congress of the European-Hematology-Association Conference Date: JUN 12-15, 2008 Conference Location: Copenhagen, DENMARK
5. JAK2V617F mutational frequency in refractory anemia with ringed sideroblasts associated with marked thrombocytosis  
 Author(s): Schmitt-Graeff, A; Teo, SS; Olschewski, M; et al.  
 Source: PATHOLOGY RESEARCH AND PRACTICE Volume: 203 Issue: 5  
 Pages: 39 Published: 2007
6. Proposed minimal diagnostic criteria for myelodysplastic syndromes Author(s): Valent, P; Horny, HP; Fonatsch, C; et al.  
 Source: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Volume: 92  
 Pages: 0220 Published: 2007 Conference Title: 12th Congress of the European-Hematology-Association Conference Date: JUN 07-10, 2007 Conference Location: Vienna, AUSTRIA
7. Genetic polymorphisms of DNA-repair- and detoxification enzymes in therapy-related AML and MDS  
 Author(s): Fischer, S; Seedhouse, C; Schulz, T; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 4223 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA
8. Multivariate evaluation of the prognostic and therapeutic relevance of cytogenetics in a merged European-American cohort of 3860 patients with MDS  
 Author(s): Haase, D; Estey, EH; Steidl, C; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 247 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA

9. Multivariate analysis suggests that the prognostic impact of poor cytogenetics is potentially underestimated in the IPSS  
 Author(s): Schanz, J; Estey, EH; Steidl, C; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 248 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA
10. Continued low-dose decitabine (DAC) is an active first-line treatment. In all cytogenetic subgroups of older AML patients: Results of the FR00331 multicenter phase II study  
 Author(s): Lubbert, M; Rueter, B; Claus, R; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 300 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA
11. Risk factors for disease progression in del(5q) MDS patients treated with lenalidomide  
 Author(s): Giagounidis, AA; Haase, S; Platzbecker, U; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 1460 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA
12. The impact of transfusion-dependency on the outcome of patients with myelodysplastic syndromes (MDS) receiving allogeneic peripheral blood stem cell transplantation after myeloablative conditioning  
 Author(s): Platzbecker, U; Germing, U; Stumpf, J; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 1467 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA
13. Polymorphisms in detoxification and DNA repair genes in myelodysplastic syndromes  
 Author(s): Seedhouse, CH; Fischer, S; Germing, U; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 2440 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA
14. Prognostic factors in treatment-related Myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML).  
 Author(s): Kendgen, A; Mende, C; Haase, D; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 2451 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA
15. Dependency of survival on additional karyotype anomalies and, bone marrow blast count in patients suffering from myelodysplastic syndromes with 5q deletion.  
 Author(s): Knipp, S; Hildebrandt, B; Jotterand, M; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 2459 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA
16. Coalescence of the german-austrian and IMRAW cytogenetic MDS databases: Modification of patient risk groups.  
 Author(s): Steidl, C; Schanz, J; Le Beau, MM; et al.  
 Source: BLOOD Volume: 110 Issue: 11 Pages: 2468 Published: 2007 Conference Title: 49th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 08-11, 2007 Conference Location: Atlanta, GA

17. The JAK2 V617F mutation identifies specific subgroups of myelodysplastic syndrome (MDS).  
Author(s): Ceasay, MM; Lea, N; Ingram, WC; et al.  
Source: BLOOD Volume: 108 Issue: 11 Pages: 2610 Published: 2006 Conference Title: 48th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 09-12, 2006 Conference Location: Orlando, FL
18. Lenalidomide is likely to improve overall survival in patients with del(5q) myelodysplastic syndrome with a complex karyotype.  
Author(s): Giagounidis, AA; Haase, S; Germing, U; et al.  
Source: BLOOD Volume: 108 Issue: 11 Pages: 4860 Published: 2006 Conference Title: 48th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 09-12, 2006 Conference Location: Orlando, FL
19. Evidence for an underestimation of the prognostic impact of poor cytogenetics within the IPSS.  
Author(s): Haase, D; Germing, U; Schanz, J; et al.  
Source: BLOOD Volume: 108 Issue: 11 Pages: 252 Published: 2006 Conference Title: 48th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 09-12, 2006 Conference Location: Orlando, FL
20. Individualizing IPSS risk assessment in myelodysplastic syndromes, by additionally taking into account age, gender and French-American-British (FAB) classification - A multicenter analysis.  
Author(s): Noesslinger, T; Tuechler, H; Germing, U; et al.  
Source: BLOOD Volume: 108 Issue: 11 Pages: 2618 Published: 2006 Conference Title: 48th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 09-12, 2006 Conference Location: Orlando, FL
21. The JAK2-V617 mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.  
Author(s): Schmitt-Graeff, A; Teo, SS; Olschewski, M; et al.  
Source: BLOOD Volume: 108 Issue: 11 Pages: 2695 Published: 2006 Conference Title: 48th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 09-12, 2006 Conference Location: Orlando, FL
22. Prognostic factors for outcome of patients undergoing allogeneic HSCT from unrelated and related donors for AML and MDS: A retrospective analysis.  
Author(s): Graef, T; Vaupel, M; Fenk, R; et al.  
Source: BLOOD Volume: 106 Issue: 11 Pages: 1147 Published: 2005 Conference Title: 47th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 10-13, 2005 Conference Location: Atlanta, GA
23. Correlation of cytogenetic findings with morphology, clinical course and prognosis in 2124 patients with MDS.  
Author(s): Haase, D; Steidl, C; Schanz, J; et al.  
Source: BLOOD Volume: 106 Issue: 11 Pages: 787 Published: 2005 Conference Title: 47th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 10-13, 2005 Conference Location: Atlanta, GA
24. Valproic acid (VPA) achieves high response rates in patients with low-risk myelodysplastic syndromes.  
Author(s): Kuendgen, A; Schmid, M; Knipp, S; et al.  
Source: BLOOD Volume: 106 Issue: 11 Pages: 789 Published: 2005 Conference Title: 47th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 10-13, 2005 Conference Location: Atlanta, GA

25. Induction of complete remission with 5-azacytidine in a patient with acute myeloid leukemia refractory to intensive chemotherapy.  
Author(s): Kuendgen, A; Graef, T; Knipp, S; et al.  
Source: BLOOD Volume: 106 Issue: 11 Pages: 4600 Published: 2005 Conference Title: 47th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 10-13, 2005 Conference Location: Atlanta, GA
26. Continued low-dose decitabine (DAC) is an active first-line treatment of older AML patients: First results of a multicenter phase II study.  
Author(s): Lubbert, M; Ruter, B; Schmid, M; et al.  
Source: BLOOD Volume: 106 Issue: 11 Pages: 1852 Published: 2005 Conference Title: 47th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 10-13, 2005 Conference Location: Atlanta, GA
27. A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes.  
Author(s): Malcovati, L; Germing, U; Kuendgen, A; et al.  
Source: BLOOD Volume: 106 Issue: 11 Pages: 788 Published: 2005 Conference Title: 47th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 10-13, 2005 Conference Location: Atlanta, GA
28. Sequential cytogenetic analyses of 577 patients with myelodysplastic syndromes: Correlations between initial karyotype, cytogenetic dynamics, and clinical course.  
Author(s): Steidl, C; Schabla, R; Germing, U; et al.  
Source: BLOOD Volume: 106 Issue: 11 Pages: 2531 Published: 2005 Conference Title: 47th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 10-13, 2005 Conference Location: Atlanta, GA
29. Treatment of del(5q) myelodysplastic syndrome with all-trans-retinoic acid and tocopherol-alpha  
Author(s): Giagounidis, AAN; Haase, S; Germing, U; et al.  
Source: BLOOD Volume: 104 Issue: 11 Pages: 4729 Published: 2004 Conference Title: 46th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 04-07, 2004 Conference Location: San Diego, CA
30. The influence of age and gender on the prognostic impact of karyotypic subgroups in myelodysplastic syndromes - a multicenter analysis.  
Author(s): Noesslinger, T; Germing, U; Hildebrandt, B; et al.  
Source: BLOOD Volume: 104 Issue: 11 Pages: 1448 Published: 2004 Conference Title: 46th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 04-07, 2004 Conference Location: San Diego, CA
31. Visualization of c-Mpl expression in ph-negative myeloproliferative diseases and so-called essential thrombocythemia with ringed sideroblasts by confocal laser scanning microscopy  
Author(s): Schmitt-Graeff, A; Thiele, J; Kvasnicka, HM; et al.  
Source: BLOOD Volume: 104 Issue: 11 Pages: 2440 Published: 2004 Conference Title: 46th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 04-07, 2004 Conference Location: San Diego, CA
32. Sequential cytogenetic analysis of 322 patients with myelodysplastic syndromes. Delineation of genetic evolution and clinical implications.  
Author(s): Steidl, C; Schabla, R; Germing, U; et al.  
Source: BLOOD Volume: 104 Issue: 11 Pages: 2368 Published: 2004 Conference Title: 46th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 04-07, 2004 Conference Location: San Diego, CA

33. Cytogenetic metaphase analysis in myelodysplastic syndromes - Diagnostic accuracy is significantly dependent on the number of metaphases analyzed.  
Author(s): Steidl, C; Hildebrandt, B; Germing, U; et al.  
Source: BLOOD Volume: 102 Issue: 11 Pages: 5042 Published: 2003 Conference Title: 45th Annual Meeting of the American-Society-of-Hematology Conference Date: DEC 06-09, 2003 Conference Location: SAN DIEGO, CALIFORNIA